How many drugs treat Staphylococcal pneumonia?

Drug Landscape tracks 10 marketed treatments for Staphylococcal pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Staphylococcal pneumonia?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/staphylococcal-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Staphylococcal pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Staphylococcal pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcal pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Zyvox	linezolid	Pfizer	Oxazolidinone Antibacterial [EPC]	Amine oxidase [flavin-containing] A	2000-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 10 drugs in Staphylococcal pneumonia
Pfizer · 7 drugs in Staphylococcal pneumonia
Bristol-Myers Squibb · 5 drugs in Staphylococcal pneumonia
GSK · 4 drugs in Staphylococcal pneumonia
Pai Holdings Pharm · 2 drugs in Staphylococcal pneumonia
Bayer AG · 1 drug in Staphylococcal pneumonia
Centre Hospitalier Universitaire Vaudois · 1 drug in Staphylococcal pneumonia
Dr Reddys Labs Inc · 1 drug in Staphylococcal pneumonia
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Staphylococcal pneumonia
Generic (originally Roche) · 1 drug in Staphylococcal pneumonia
Generic (originally Upjohn/Pfizer) · 1 drug in Staphylococcal pneumonia
HaEmek Medical Center, Israel · 1 drug in Staphylococcal pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcal pneumonia:

Cite this brief

Drug Landscape (2026). Staphylococcal pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcal-pneumonia. Accessed 2026-06-10.

Staphylococcal pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing